Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Infections

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Uterine Cervical Neoplasms

Warts

Condylomata Acuminata

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

All Drugs and Chemicals

Vaccines

An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.

A delayed dose 2 was defined as \> 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.

An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as \>180 days after dose 2.

A delayed dose 2 was defined as \> 90 days after dose 1 and a delayed dose 3 was defined as \>180 days after dose 2.

Both 2nd and 3rd doses on time

2nd dose late and 3rd dose on time

2nd dose on time and 3rd dose late

Both doses late

Emmanuel B Walter, MD

The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine delivered according to the recommended dosing schedule.

This was a prospective observational study of healthy 9-18 year old female patients receiving either a second or third dose of HPV vaccine as part of their well child care. Immune responses to HPV types 6, 11, 16 and 18 were measured both before and 1 month after the third dose of HPV vaccine with the purpose of comparing the immune responses to HPV vaccine when administered at naturally occurring longer dosing intervals to the immune response to HPV vaccine when administered as routinely recommended.

In addition, girls receiving a 3rd dose of HPV vaccine as well as concomitantly administered vaccines by injection were randomized to receive either the HPV vaccine first or their concomitantly administered vaccines first. Pain following vaccination was assessed in each arm using the Faces Pain Scale - Revised.

Please note: This record refers only to the observational portion of the study. Please refer to NCT00862810 for the results of the randomized portion of the study.

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

Alternate Dosing Schedules Study for HPV Vaccine

Geometric mean titer (GMT) of antibody to HPV type 6

Geometric mean titer (GMT) of antibody to HPV type 11

Geometric mean titer (GMT) of antibody to HPV type 16

Geometric mean titer (GMT) of antibody to HPV type 18

Centers for Disease Control and Prevention

Duke University

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Alternate Dosing Schedules Study for HPV Vaccine (ADS)	NCT02280642	Cervical Cancer Genital Warts	Both 2nd and 3r... 2nd dose late a... 2nd dose on tim... Both doses late	9 Years - 18 Years	Duke University
Alternate Dosing Schedules Study for HPV Vaccine (ADS)	NCT02280642	Cervical Cancer Genital Warts	Both 2nd and 3r... 2nd dose late a... 2nd dose on tim... Both doses late	9 Years - 18 Years	Duke University

Spots Global Cancer Trial Database for 2nd dose on time and 3rd dose late